Bhandari M, Anand AS, Verma K, Regmi K, Amitabh, Prasad DN, Kohli E
Authors not listed · 2025
COVID antiviral study stopped early due to low enrollment, preventing definitive conclusions about treatment benefits.
Plain English Summary
The RECOVERY trial tested two COVID-19 antiviral drugs (molnupiravir and nirmatrelvir-ritonavir) in 1,060 hospitalized patients across multiple countries. Neither drug improved survival rates or reduced hospital stays when added to standard care. The study was stopped early due to low enrollment, limiting the ability to detect potential benefits.
Why This Matters
This study highlights a critical issue in medical research that parallels challenges we see in EMF health studies: the difficulty of conducting adequately powered trials to detect meaningful health effects. The RECOVERY trial's early termination due to low recruitment demonstrates how practical constraints can limit our ability to definitively assess health interventions. This mirrors the EMF research landscape, where studies often lack sufficient sample sizes or duration to capture subtle but potentially significant long-term effects. The reality is that absence of evidence isn't evidence of absence - particularly when studies are underpowered to detect clinically meaningful differences, as acknowledged by the researchers themselves.
Exposure Information
Specific exposure levels were not quantified in this study.
Show BibTeX
@article{bhandari_m_anand_as_verma_k_regmi_k_amitabh_prasad_dn_kohli_e_ce2318,
author = {Unknown},
title = {Bhandari M, Anand AS, Verma K, Regmi K, Amitabh, Prasad DN, Kohli E},
year = {2025},
doi = {10.1016/s1473-3099(25)00093-3},
}